AnaptysBio Inc - Company Profile
Powered by 
All the data and insights you need on AnaptysBio Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date AnaptysBio Inc Strategy Report
- Understand AnaptysBio Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
AnaptysBio Inc (AnaptysBio) is a clinical-stage biotechnology company that focuses on the development of antibody candidates for the treatment of atopic dermatitis, ovarian cancer, lung cancer, asthma, psoriasis, inflammation, and other indications. The company’s pipeline product candidates include imsidolimab, an anti-IL-36R antibody; rosnilimab (ANB030); ANB032: Anti-BTLA Modulator; Etokimab (IL-33); and ANB033, an IL-15 and IL-2 receptor.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company has developed an innovative platform for antibody research aimed at discovering and optimizing therapeutic antibodies that can effectively modulate immune function. These antibodies can act as antagonists or immune cell modulators. The discovery and optimization process primarily focus on the Fab domain of the antibody. To imitate the natural process of somatic hypermutation (SHM) employed by the human immune system, the company utilizes a technology that involves the expression of a key enzyme called activation-induced cytidine deaminase (AID). It spent US$88.8 million in research and development in FY2022.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer